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Aim:  To assess the role of second resection in T1G3 bladder tumors 
Material and Methods:  This  is a prospective  study conducted  in  the Department of Urology, Christian 
Medical College, Vellore from April 2009 to December 2010. All T1G3 lesions were included in this study 
and variables  like size, multifocality, characteristics of the  lesions were analysed. Prevalence of second 
resection was calculated along with 95% CI. Chi square test was used to assess association between the 
categorical variables and tumor positivity  in second resection. Thirty seven patients were diagnosed to 
have T1G3 disease, of which 27 had a second resection done. Hence, these patients were taken as the 
study group and the sample size. 
Results:    Fifty five percent of the lesions were solitary papillary and 09% were multiple papillary.  
All our resections had muscularis propria sampled at the end of the resection and separately sent for HPE 
which were tumor free. Thirty three percent of patients had residual disease at second resection and 
3.7% were upstaged. Eighty five percent of the patients with solitary papillary lesions did not have any 
residual disease. When size also was considered, none of the patients with tumor size less than 3cms 
and solitary papillary lesions had a residual disease in second resection.  
Conclusion:  Patients  with  T1G3  tumors  do  not  represent  a  homogenous  group.  Second  TUR  is 
recommended  in  patients  with  high  grade  T1  urothelial  bladder  carcinoma  as  it  identifies  residual 
disease  and  invasive disease.  In our  study,  among  the patients with  solitary papillary  lesion  and  size 
<3cm, none had tumor  in the second TUR and therefore the need for a second TUR  is questionable  in 
this group. 
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INTRODUCTION 
Transitional cell carcinoma (TCC) of the urinary bladder has a broad 
spectrum of disease course and treatment. The diagnosis and accurate staging 
of the tumor is an important initial step to determine the most appropriate 
management strategy. 
Epidemiology:  
TCC of the urinary bladder is the ninth most common cancer in worldwide 
cancer incidence. It is the 7th most common cancer in men and ranks 17th in 
women 1. After prostate cancer, it is the second most common urological 
malignancy. The incidence of bladder cancer varies significantly all over the 
world, with Egypt, Eastern Europe, and North America having the highest 
incidence rates, and Asian countries the lowest rates 2. More than 90% of new 
cases occur in people in the 6th decade, but the disease may occur in younger 
population as well 3. The mean age of the patients diagnosed with bladder cancer 
is 69 years for men and 71 for women and the estimated ratio between men and 
women is 3.8/1 4. 
Risk factors: 
Cigarette smoking and occupational exposure to urothelial carcinogens 
are the two most well-established risk factors for bladder tumors 5. Fifty percent of 
bladder cancer in men and 35% in women is due to cigarette smoking 6. Cigarette 
smokers have a 2 to 4 fold increased risk of bladder cancer compared to non-
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smokers 7.  The incidence of urinary bladder cancer is directly related to the 
duration of smoking and the number of cigarettes smoked per day 8.  
Sixteen to 24% of all the bladder cancers are due to occupational 
exposure to urothelial carcinogens and is the second most important risk factor 9. 
Aromatic amines  used in the chemical, rubber, and dye industries (eg, benzidine, 
2-naphthylamine, 4-aminobiphenyl, o-toluidine, and 4-chloro-o-toluidine) and 
polycyclic aromatic hydrocarbons (PAHs) used in the aluminum, coal, and roofing 
industries are all known to be associated with the development of bladder cancer. 
An increased risk of bladder cancer has also been reported in painters, 
varnishers, and hairdressers 2.  
Chronic urinary tract infections, cyclophosphamide use, and exposure to 
radiotherapy are the other known causes which are associated with urinary 
bladder malignancy 10. Long term irritation of the bladder by indwelling catheters 
or stones, is related to development of squamous cell carcinoma of the bladder. 
Schistosomiasis is endemic in Egypt and the Middle East and is considered to be 
a definite cause of bladder cancer 11.   
 Inadequate consumption of fruits, vegetables, and certain vitamins may 
also play a role in the development of bladder cancer. Although it has been 
suggested that coffee consumption and artificial sweeteners may be associated 
with an increased risk of bladder cancer, results from epidemiologic studies 
investigating these agents have been inconclusive 2. There is an increased risk of 
bladder cancer in individuals with a family history of cancer. A population-based, 
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family case control study found an almost 2-fold increased risk among first-
degree relatives of patients with urothelial cell carcinoma 12. 
Pathology: 
The urinary tract extends from the renal pelvis to the urethra and is 
covered with transitional epithelium, also called the urothelium. Normal 
urothelium is three to seven layers thick. The external layer consists of large 
umbrella cells. The urothelium rests on the basal membrane of the lamina propria 
which consists of the subepithelial tissue and muscularis mucosa, followed by the 
muscularis propria (detrusor) and then the fat and the large venous plexus.  
Transitional cell carcinoma bladder is the most common primary 
pathologic subtype of bladder cancer and is observed in >90% of tumours. Other 
subtypes are squamous cell carcinoma and adenocarcinoma and are less 
common and occur in approximately 5% and 1% of bladder cancers, 
respectively2.  
Classic TCC grows exophytically into the lumen of the urinary bladder and 
resembles swaying seaweed on cystoscopy. TCC can also grow as a sessile 
tumor in the bladder wall. A special variant of TCC is carcinoma in situ (CIS), a 
flat tumor, often multifocal and seen as velvety, red edematous patches on 
cystoscopy. There are three different kinds of CIS: 
1. Primary CIS is CIS with no previous history of bladder cancer. 
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2. Secondary CIS is when CIS occurs with previously diagnosed TCC 
bladder. 
3. Concomitant CIS implicates co-existing papillary or nodular tumor and 
CIS. 
Staging and Grading: 
Stage and grade are significant prognostic factors for recurrence, 
progression, and survival. They are critical for the appropriate treatment and 
management of TCC bladder. The most widely used and universally  accepted 
staging system is the tumour-node-metastases (TNM) system (Table 1).  
The new classification for grading of non-invasive urothelial tumours was 
proposed by the World Health Organization (WHO) and the International Society 
of Urological Pathology (ISUP) and published by the WHO in 2004 (Table 2) 13. It 
differentiates between papillary urothelial neoplasm of low malignant   potential 
(PUNLMP) and low-grade and high-grade urothelial carcinomas. The PUNLMP 
are lesions that do not have cytological features of malignancy but show normal 
urothelial cells in a papillary configuration. They have a negligible risk for 
progression, but still have a tendency to recur. The intermediate grade (grade 2), 
which was the subject of controversy in the 1973 WHO classification, has been 
eliminated 14. 
 
 
6 
 
Table 1: TNM staging of bladder cancer. 
T: Primary tumour  
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
Ta  Non-invasive papillary carcinoma 
Tis Carcinoma in situ: ‘‘flat tumour’’ 
T1  Tumour invades subepithelial connective tissue 
T2  Tumour invades muscle 
T2a:  Tumour invades superficial muscle (inner half) 
T2b:  Tumour invades deep muscle (outer half) 
T3  Tumour invades perivesical tissue: 
T3a:  Microscopically 
T3b:  Macroscopically 
T4  Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, 
abdominal wall 
T4a:  Tumour invades prostate, uterus, or vagina 
T4b:  Tumour invades pelvic wall or abdominal wall 
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N: Lymph nodes 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in a single lymph node ≤2 cm in greatest dimension 
N2  Metastasis in a single lymph node >2 cm but not >5 cm in greatest 
dimension, or multiple lymph nodes, none >5 cm in greatest dimension 
N3  Metastasis in a lymph node >5 cm in greatest dimension 
M:  Distant metastasis 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
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Table 2 – World Health Organization (WHO) grading of urinary tumours in 
1973 and 2004 
 WHO 1973 
Urothelial papilloma 
Grade 1: well differentiated 
Grade 2: moderately differentiated  
Grade 3: poorly differentiated 
WHO 2004 
Urothelial papilloma 
PUNLMP 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
PUNLMP = papillary urothelial neoplasm of low malignant potential. 
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Non Muscle Invasive Bladder Cancer (NMIBC): 
Haematuria is the most common finding in non-muscle-invasive bladder 
tumours. Bladder irritation, dysuria, or urgency may be symptoms of CIS. 
Approximately 75–80% of bladder tumours present as non–muscle invasive 
disease and the remainder present as muscle-invasive disease. In NMIBC, 
approximately 70% present as Ta lesions, 20% as T1 lesions and 10% present 
as CIS or Tis lesions 10. NMIBC   represents a heterogeneous group of tumours 
with completely different oncologic outcomes. This heterogeneity in bladder 
tumors complicates the ability to compare the efficacy of different treatment 
modalities and thereby establish unified treatment recommendations. Therefore, 
risk stratification is imperative for classifying patients with similar risks of 
recurrence and progression, and it helps to determine the appropriate 
management strategies for each risk category 2.  
T1G3: 
T1G3 bladder tumor, a high grade lesion invading the lamina propria and 
yet to involve the muscularis propria, is highly malignant in the non-muscle 
invasive group 15. T1G3 tumours have a high propensity to recur and progress to 
muscle invasion and are associated with a significant risk of metastasis and 
death. Eventhough T1G3 is classified as non muscle invasive tumor, about 15 – 
20% progress to higher stage and nearly 75% develop recurrence 16. 5% to 30% 
of patients with T1G3 ultimately die of bladder cancer within 5 – 10 years 15,17. 
The biological characteristics of these tumors have been proved to be same as 
that of the muscle invasive transitional cell carcinoma (TCC) 16.  Nevertheless, 
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many of these tumors can be treated successfully with bladder preservation 
approaches. The dilemma facing the urologist is how best to treat these tumors in 
a timely manner so that the chances of bladder preservation and cancer control 
are maximized while the risks of overtreatment with radical therapy are 
minimized. 
Factors predicting the poor prognosis of T1G3 tumors are multiple tumors, 
high grade lesions, larger size, sessile pattern, associated CIS and early 
recurrence of tumor after primary transurethral resection of bladder tumor 
(TURBT) 17,18.  A number of molecular and genetic prognostic factors have also 
been studied, but none of these have been validated prospectively 19.  Besides 
these, the duration of disease also influences the disease specific survival 20.  
TURBT and intravesical therapy is now accepted as the reference 
standard for T1G3 tumors. The primary transurethral resection might leave 
residual disease, more so in multiple tumors, thereby increasing the risk of early 
tumor recurrence and stage progression even after intravesical therapy 21. 
Second resection of T1G3 tumors may help to eradicate the residual disease and 
also to identify the early recurrence 21,22. Keeping in mind the limitations of the 
current staging modalities, these tumors are understaged and a patient may 
receive inadequate treatment to a potentially curable disease 23. Therefore a re-
resection is routinely advised in all T1G3 tumors.  
For all cases of newly diagnosed T1G3 TCC, a secondary TUR 4–6 wk 
after the primary TUR is strongly recommended. The advantages of a second 
TUR are many and discussed in detail. The morbidity associated with invasive re-
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resection, the cost of the treatment and the delay in intravesical therapy 
questions whether re-resection is necessary in all T1G3 lesions 24. Even after a 
satisfactory primary resection and a good muscle in the resected specimen, is it 
necessary to proceed with a re-resection? 
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REVIEW OF LITERATURE 
T1G3 bladder cancer is associated with an aggressive course among 
superficial bladder tumors. They have a high propensity to recur and also to 
upstage to T2 disease. They are associated with a significant risk of metastasis 
and death.  Literature shows long-term death rates as high as 34% 25. An 
extremely variable 5-year progression rate ranging from 20 to 75% exists, 
probably due to the different risk subgroups in this spectrum of T1G3 26. 
Identifying these subgroups and the associated risk factors will help plan an 
effective management. The goal of the treatment of T1G3 bladder cancer is to 
decrease the mortality, ensure reduced morbidity and achieve a good quality of 
life. The dilemma facing the urologist is how best to treat these tumors in a timely 
manner so that the chances of bladder preservation and cancer control are 
maximized, while the risks of overtreatment with radical therapy are minimized 27. 
To assess the role of conservative management in pT1G3 bladder cancer, 
a number of issues need to be considered:  
−  Is it really a pT1G3 tumor? 
− The variability of pT1G3 bladder cancer 
− The quality of clinical data 
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To confirm the stage and grade as pT1G3 
The management protocol for patients with different stages of the disease 
(pTa, pT1 and pT2 or greater tumors) varies substantially 28. Pathologists hold a 
key position in making a diagnosis and in commenting on the accurate stage & 
grade of a patient’s tumor. They must be presented with suitable material along 
with relevant clinical information: the case is then best reviewed in the setting of a 
multidisciplinary uro-oncology meeting 29. The pathologist must receive muscle-
bearing specimens to determine whether muscle invasion has occurred.  In 40% 
of 58 patients with apparently pT1 disease reviewed by Herr, muscle had not 
been included in the resection specimens from the referring hospital 30. The 
uniformity of the pathologist’s report, assuming adequate specimens, also needs 
to be accounted for. Evidence suggests  that not only do experienced uro-
pathologists vary in their diagnoses, they also may be inconsistent regarding the 
same specimen 31.Results in one study revealed that general pathologists tend to 
overstage tumors, but undergrade them 32. A close liaison between the urologist 
and the pathologist, preferably in a multidisciplinary team meeting is hence 
important.  
The variability of pT1G3 bladder cancer 
Data on the untreated natural history of pT1G3 tumors is sparse, as these 
tumors generally require more than just a TURBT 33,34. Heney and colleagues 
reported a progression rate of 48% at around 3 years in 27 patients with pT1G3 
tumors 35. This, however, was before the widespread use of intravesical 
treatments such as BCG. They were considered as tumors with high potential to 
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invade the muscle.It was noticed that the risk of progression and death from 
disease for patients with pT1G3 tumors is up to 10-fold greater than that for 
patients with other pTa and pT1 tumors 29. As long-term data on the use of 
intravesical Bacillus Calmette-Gue´rin (BCG) has become available over the last 
twenty years, the idea of the so-called ‘‘rule of threes’’ has emerged, viz., of all 
the patients treated with BCG, approximately one third survive with their bladder 
intact, around a third require radical cystectomy, and around a third die of their 
disease 36. This difference in outcome varies markedly from the very low 
progression rates seen with pTa tumors 35, to the relentlessly aggressive course 
of muscle-invasive disease. The dilemma, therefore, is to treat adequately, but 
not to over-treat. The outcome for patients with pT1G3 tumors also seems to be 
strongly influenced by the presence or absence of carcinoma in situ (CIS) 37. The 
presence of associated CIS must therefore be carefully considered in the case for 
conservative treatment of a patient with a pT1G3 tumor. 
The quality of clinical data 
Patients may present with primary or recurrent tumors, with and without 
CIS, and with or without other factors that may influence the outcome, such as 
the presence of tumor in the prostatic urethra or the upper tracts 38. Even with the 
information obtained from the systematic reviews and meta-analyses, at present, 
the ‘‘best’’ way to manage patients with pT1G3 bladder cancer is not clear. 
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PROGNOSTIC FACTORS 
The important prognostic factors which help in predicting the outcome of 
the T1G3 tumors following the initial TURBT include early recurrence or new 
occurrence, multiplicity of the tumor lesions, size of the lesion, the presence of 
associated carcinoma in situ along with the T1 tumors, urothelial carcinoma 
involving the prostatic urethra or the ducts and the depth of the lamina propria 
involved 39.  T category and the grade of the tumor do not significantly influence 
the recurrence rate. Recurrence rate depends mainly on the multiplicity of tumors 
(single tumor, 51% recurrence at 5 years; multiple tumors, 91%), the previous 
recurrence rate, or the recurrence at 3 months 40. In contrast, the grade and, to a 
lesser extent, the stage of disease is the most important prognostic factors for 
disease progression. The size of the tumor, the presence of tumor-associated 
CIS and the involvement of the prostatic urethra also carry a worse prognosis 41. 
Increasing tumor size portends an increased risk for undetected infiltration 
of the lamina propria. The depth of the lamina propria involved is also a 
significant prognostic factor. The more the lamina propria appears infiltrated, the 
earlier are the chances of dissemination. Multifocality of the tumor carries a 
worse prognosis. The reasons for this are multiple. Multifocal tumors tend to be 
understaged, and the chances of complete resection decrease with the number 
of tumors 42. Multifocality indicates the susceptibility of the entire urothelium to 
develop tumours (field change effect). There is thus a strong need for the close 
follow-up of the urethra and the upper urinary tract after cystectomy and of the 
bladder in patients selected for an organ preserving approach 42.  
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It has been seen in recent reports that patients with TaG3 tumors are also 
at high risk of life-long progression, not very different from that of patients with 
T1G3 tumors. Herr 43 followed 125 such patients for 15 years and observed 
progression in 39% and cancer related death in 26%. Similar data was reported 
by Lebret et al 44  where 32 patients with TaG3 tumors followed for 4 years had a 
25% progression rate with 12% cancer-related deaths.  
Apart from these unfavourable prognostic factors, the duration of the T1G3 
disease also influences disease-specific survival. In a large study 45, on follow up 
for 8 years, 50% of the G3 patients either died from bladder cancer or developed 
muscle-invasive disease. After 15 years, more than half the patients with T1 
disease developed a muscle-invasive tumor and a third died from metastatic 
carcinoma 46.  
Molecular and genetic aspects such as altered expression of p53 have 
been implicated in the aggressive biological behavior of the bladder tumors. p53 
mutations have been found in many cancers, including TCC. P53 overexpression 
is an independent predictive factor of recurrence for T1G3 bladder cancers. 
Retinoblastoma (Rb) gene was also evaluated as a possible predictive factor for 
the disease progression. Abnormal expression of p53 was found to be 
significantly responsible for the tumor progression 10.  
As patients with T1G3 tumors have a life-long risk of progression some 
surgeons advocate cystectomy at the time of diagnosis 47,48. The ideal course 
would be to find a compromise, i.e. to be as conservative as possible and at the 
same time avoid progression and death from bladder cancer 41. Considering the 
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factors discussed, treatment may be improved by risk stratification and patient 
selection. Identifying the precise subset of patients with T1 bladder tumor who 
are at risk of disease progression is a major goal.  
PREDICTING RECURRENCE AND PROGRESSION 
This heterogeneity in bladder tumours complicates the ability to compare 
the efficacy of different treatment modalities and thereby establish unified 
treatment recommendations. Risk stratification is therefore imperative for 
classifying patients with similar risks of recurrence and progression. It also helps 
determine the appropriate management strategies for each risk category. To 
date, the European Organisation for Research and Treatment of Cancer 
(EORTC) risk tables are considered the most reliable tools for estimating 
progression and/or recurrence of NMIBC. The EORTC scoring system combines 
data on previous tumour recurrence rate, number of tumours, tumour diameter, T 
category and WHO grade, and the presence or absence of concomitant CIS to 
estimate the risk of recurrence and progression 49. The EORTC scoring system is 
shown in Table 3, and the EORTC risk tables are shown in Table 4.  
  
19 
 
Table 3: European organization for research and treatment of cancer 
weighting used to calculate recurrence and progression scores 49 
FACTOR   RECURRENCE  PROGRESSION 
 
Number of tumors 
 Single    0   0 
 2 – 7    3   3 
 >8    6   3 
Tumor diameter 
 <3    0   0 
 ≥3    3   3 
Prior recurrence rate 
 Primary    0   0 
 ≤1 recurrence per year 2   2 
 >1 recurrence per year 4   2 
Category 
 Ta    0   0 
 T1    1   4 
Carcinoma insitu 
 No    0   0 
 Yes    1   4 
Grade (1973 WHO) 
 G1    0   0 
 G2    1   0 
 G3    2   5 
 
Total Score    0 – 17   0 – 23  
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The main limitation of the EORTC risk tables is that the risk groups were 
based on patients who were mostly treated with older intravesical chemotherapy 
regimens 49. The use of a single, immediate chemotherapeutic instillation, 
induction and maintenance BCG, and repeat transurethral resection of the 
bladder tumour (TURBT) were therefore not considered in the development of 
these tables. Improvements in chemotherapy administration, along with the 
increased use of BCG, may reduce the predictability of these tables. Notably, 
very few cases of CIS were included in the studies used as the basis for this 
scoring system and, hence, the EORTC tables may not accurately predict 
recurrence and progression in these patients.  
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Table 4: Probability of recurrence and progression according to score 49 
 
Recurrence   Probability of recurrence   Probability of recurrence 
score   at 1 yr (95% CI)    at 5 yrs (95% CI) 
 
0   15% (10%,19%)   31% (24%, 37%) 
1-4   24% (21%,26%)   46% (42%, 49%) 
5-9   38% (35%,41%)   62% (58%, 65%) 
10-17   61% (55%,67%)   78% (73%, 84%) 
 
Progression     Probability of progression        Probabilityof progression 
score   at 1 yr (95% CI)    at 5 yrs (95% CI) 
 
0   0.2% (00%,0.7%)   0.8% (0%, 1.7%) 
1-4   01%  (0.4%,1.6%)   06% (05%, 08%) 
7-13   05%  (04%,07%)   17% (14%, 20%) 
14-23   17%  (10%,24%)   45% (35%, 55%) 
 
TREATMENT OPTIONS IN T1G3 BLADDER CANCER: 
Transurethral Resection of Bladder Tumor 
Transurethral resection of the bladder tumor (TURBT) is the first step in 
the initial treatment of bladder cancer.  A TURBT is both diagnostic and 
therapeutic, and the procedure provides critical staging information. In the setting 
of a TURBT, the configuration (flat, sessile, or papillary), location (trigone, base, 
dome, or lateral walls), size (centimeters), and number of tumors should be 
noted. Tumors have to be completely resected and muscularis propria must be 
included in the specimen to ensure adequate resection, thorough histological 
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evaluation, and accurate clinical staging. Larger tumours must be resected 
separately in fractions, which include the exophytic part of the tumour, the 
underlying bladder wall with the detrusor muscle, and the edges of the resection 
area. The specimens from different fractions have to be referred to the 
pathologist in separate containers. Cauterization has to be avoided as much as 
possible during the resection to prevent tissue destruction. The pathologic report 
should specify the grade of the lesion & the depth of tumour invasion into the 
bladder wall. It must also and give information on whether the lamina propria and 
muscle are present in the specimen. A complete and correct TUR is essential for 
the prognosis of the patient. 
Role of random biopsies 
In the 1970s, the bladder cancer was believed to be a multifocal tumor 
with co-existing CIS distant from the primary tumour 40. Biopsies from the normal 
looking mucosa were also recommended 50. The role of random biopsies was 
questioned and in the recently published EAU guidelines: It is not routinely 
recommended.  
Fujimoto et al. 51 and Van der Meijden et al 52 assessed the usefulness of 
random bladder biopsies of normal bladder mucosa after TURBT.  Cancer was 
identified in only few biopsies and was thought to be un-warranted. If needed, 
multiple random biopsies were needed only in patients with multiple papillary 
tumors or in those with positive cytology results. Conversely, May et al 53 found 
that random bladder biopsies altered therapy in 7% of 1033 consecutive patients. 
In fact, in 14 patients, malignancy was identified in only the random biopsies and 
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not in the resection of the primary tumor. Importantly, however, these 
investigators excluded patients with small, primary, solitary bladder tumors. It was 
concluded that the patients with low- risk–appearing tumors and negative 
cytology results need not undergo random biopsy. 
 Role of Immediate Adjuvant Intravesical Chemotherapy 
Clear consensus exists on the role of prophylactic chemotherapy in the 
first 6 hours after TUR.  In an effort to reduce this risk, many trials have 
investigated the use of prophylactic or adjuvant intravesical therapy at the time of 
TURBT. Tolley et al 54 performed a multicenter, randomized trial of 502 patients 
with either Ta or T1 urothelial carcinoma. Those who received intravesical 
mitomycin C (MMC) within 24 hours of TURBT had a statistically significant 
decreased risk of tumor recurrence versus those who received placebo. Sylvester 
et al.55 performed a meta-analysis on this and concluded that adjuvant 
intravesical therapy is the treatment of choice in patients with a single, low-grade 
superficial bladder tumor and should be the initial treatment (before subsequent 
intravesical BCG) in those with higher-risk bladder tumors. Multicenter, 
randomized, prospective studies demonstrate that the risk of recurrence can be 
reduced by half at 2 years and by 15% at 5 years with a single dose of adjuvant 
intravesical chemotherapy 54. Routine use of prophylactic chemotherapy after 
TUR can thus be recommended. Contraindications to its use include very deep 
resections, bladder perforation, and prior documented allergic reaction. Although 
a wide variety of chemotherapeutic agents were used in the pooled trials 
(mitomycin C [MMC], doxorubicin, epirubicin, and thiotepa), the majority of 
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centres use MMC (40 mg in 40 cc of saline) as the prophylactic 
chemotherapeutic agent of choice. 
A Second TURBT 
T1G3 TCC of the bladder is associated with a significant risk of tumor 
progression and recurrence when transurethral resection (TUR) is the only 
treatment. Adjuvant immediate post TUR intravesical chemotherapy or 
maintenance immunotherapy can reduce this risk; however, long-term results of 
more than 15 years of follow-up indicate that almost 50% of the patients may end 
up in a radical surgery for the disease, or even die due to the cancer. The 
alternative to TUR is cystectomy at either the initial presentation or time of first 
recurrence. Although the results of this treatment strategy are encouraging, an 
unknown percentage of patients will lose their bladder and go on to experience all 
possible complications of urinary diversion unnecessarily- this option does seem 
to be overkill.   
The concern of conservative treatment lies in the quality of TUR. With the 
available literature it is  evident that a ‘perfect TUR’ cannot be performed on 
every patient, i.e. macroscopical clearance of the tumor from the  bladder,  
separate resection of the tumor base, inclusion of the deep muscle in the 
specimen and separate biopsies of the borders of  the resection area. Even in 
cases of a so-called ‘correct TUR’, a significant proportion of residual tumors is 
left behind and will be the source of local recurrence or progression. In addition, 
TUR specimens may be difficult to diagnose accurately, especially with respect to 
grade & stage.  
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Literature demonstrates that the routinely performed second TUR detects 
residual tumors of similar or higher stage in a significant percent of patients. The 
clinical implications of these findings can be quite significant, as the absence or 
presence of tumor may determine whether patients undergo conservative or 
aggressive treatment. Moreover, results of various retrospective studies support 
this suggestion 10,19. The TUR after incomplete resection resulting from factors 
such as multiplicity, size, and location must be called repeat resection. If a 
second intervention is done to provide additional pathologic information for the 
muscularis propria, it has to be called re-staging TUR. The term second TUR is to 
be used only if the procedure is done after a complete and correct TUR. For all 
cases of newly diagnosed T1G3 TCC, a second TUR after the primary TUR is 
strongly recommended. In cases when a second TUR in a T1 is considered 
necessary to secure the completeness of the initial resection, the question arises: 
When should it be done? Several authors have shown that a second TUR can be 
performed safely a  week  after the first TUR 56, although proposed time frames 
range from 7 days to 3 months 56.The argument that this strategy should be 
based on the result of the second TUR indicates that this procedure should be 
done as early as possible. Thus, there is no reason to wait three months unless a 
second resection is not performed (as for cases with an intact mucosa and 
negative urine cytology) 56.   The advantages of performing a second TUR are 
manifold: It provides more accurate staging, detects and potentially clears the 
entire residual tumor and is helpful in prognostication. Second TUR reduces 
recurrence and also increases the recurrence-free interval and the progression-
free survival.  
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Second TUR is of particular importance as the probability of understaging 
a T1G3 tumour ranges from 20–70%, depending on the presence of muscularis 
propria in the sample 27. Herr 30 retrospectively evaluated the difference in the 
pathologic diagnoses between an initial TURBT and a second TURBT in 150 
patients. The results of the second TURBT altered the treatment in 33% of the 
patients. Importantly, he noted the inability to correctly diagnose T1 tumors 
without muscle in the specimen. Of 23 patients with T1 lesions without muscle in 
the primary resection, 11 (49%) were upstaged to T2 lesions after review of the 
second TURBT specimen. Dutta et al. 57 similarly reported a 64% risk of 
understaging T1 lesions when muscle was absent versus 30% when muscle was 
present in the TURBT specimens. Kla¨n et al. demonstrated that patients who 
initially had a fractionated TUR had a reduced rate of residual tumor (36.7%) 
compared to patients in whom a separate resection biopsy of the tumor bed was 
not performed (56.3%) 56. If muscle is absent from the initial TUR, a repeat 
resection is essential because of the high rate of understaging 27. Even with 
muscularis propria sampling at the first resection, several reports have proven 
occult T2 disease in up to 10% of second resections 27. The high incidence of 
understaging at initial resection has been confirmed by analyzing the cystectomy 
specimens. In one study, 78 patients with non muscle invasive bladder cancer, 
who underwent cystectomy, 37% of the specimens showed muscle involvement 
48. As a second TUR often upstages T1 lesions and/ or provides additional 
pathologic information that can alter management decisions 27, repeat resection 
is indispensible in the T1G3 management armamentarium 27. 
 
27 
 
Divrik et al 58 report that doing a second TUR in patients with T1 tumors 
reduces the risk of bladder cancer recurrence and progression. A total of 210 
patients were randomized to one of two groups. An initial TUR was performed in 
both groups, followed by a second TUR in one group only. This was done 2–6 
weeks after the initial resection. Residual tumor was detected in 35 of 105 
patients in the restaged group, and 8 patients were upstaged to T2. Recurrence, 
progression, and disease-free survival were followed in all patients, and 
significantly higher levels of recurrence and progression were seen in the patients 
who had not undergone a second TUR. Tumor recurrence occurred in 37 of 93 
patients in the group who underwent a second TUR, and 70 of 98 patients in the 
other group, while progression was seen in 6.5% of patients in the second TUR 
group, compared with 23.5% of patients who did not undergo a second TUR. 
There were also more cancer- related deaths among the patients who did not 
undergo a second TUR - 11 deaths in 35 patients in this group, compared with 5 
deaths in 30 patients in the group with a second TUR. Overall survival was 67.7% 
and 64.3% in the second TUR and without a second TUR groups respectively. 
In addition to the diagnostic benefit, repeat TUR also has the ability to 
detect and potentially clear residual TCC. Since at least 27% of patients harbour 
residual tumour (with the highest reported rates of 62%) 27, repeat resections may 
have a therapeutic benefit. Zurkirchen et al. 59 retrospectively analyzed patients 
who underwent second TURBT within 6 weeks of their initial resection and found 
that 37% of patients with initial T1 bladder tumors had residual tumors on second 
resection. Grimm et al.60 similarly analyzed retrospectively 83 patients who 
underwent a second TURBT.  Residual tumor was found in 33% of cases, 
including 53% of those with initially diagnosed T1 bladder tumors. On univariate 
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analysis, both tumor stage and grade were identified as predictive for residual 
tumor on second TURBT. After 5 years, there was a significant decrease in 
disease-free survival between those who underwent a second TURBT and those 
who did not (63% and 40%, respectively). Brauers et al. 23 evaluated 42 patients’ 
withT1 bladder tumors and found that 24% of patients were upstaged to T2 or 
CIS on second TURBT. Schips et al. 24 prospectively evaluated the findings at 
first and second TURBT for patients with high-grade T1 bladder tumors and 
reported residual disease in nearly 50% of patients. Both multifocality and tumor 
grade increased the risk of finding residual tumor on second TURBT.   
Early repeat TURBT can be justified for the purposes of identifying 
understaged T2 tumors that would benefit from prompt surgery (cystectomy). In a 
series  of 189 patients who underwent cystectomy within 3 months of diagnosis of 
muscle- invasive disease,  there was a significantly better 5-year progression-free 
survival compared with those in whom cystectomy  was performed  in more than 
3 months after diagnosis (55% and 34%, respectively) 19. In summary, these 
studies show that the risk of upstaging on second TURBT is >30% if muscle is 
present in the specimen and even higher if muscle is not present 57. Further, the 
risk of residual tumor on second TURBT is also significant. The risk for even 
solitary, papillary-appearing tumors is 24% to 27% 59.  
An appreciated advantage of repeat TUR is prognostication. Although 
upstaging of T1G3 lesions to pT2 disease or higher automatically selects patients 
for radical therapy, Herr and colleagues showed that evidence of T1 disease on 
repeat TUR portends future muscle invasion 27. Of 92 T1 patients with residual T1 
disease at second resection, 82% progressed to muscle invasion by 5 yr. In 
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contrast, of 260 T1 patients who had no lamina propria invasion on a second 
TUR, only 19% progressed at 5 yr. Based on these results, residual T1 TCC on 
second TUR was deemed a negative prognostic indicator and a potential 
indication for immediate cystectomy in T1G3 patients. Due to these significant 
advantages, it is recommended that a second TURBT be considered for all 
patients with high-grade T1 urothelial TCC. 
Additional Intravesical chemotherapy 
Intravesical chemotherapy prevents recurrence but not progression, as 
confirmed by a meta-analysis comparing intravesical chemotherapy to TUR alone 
61. Two other meta analyses also demonstrated the efficacy of intravesical 
chemotherapy in decreasing the risk of tumour recurrence 62. It is still 
controversial as to how long and how frequently intravesical chemotherapy 
instillations need to be given. From a systematic review of the literature of 
randomised clinical trials, comparing different schedules of intravesical 
chemotherapy instillations, one can only conclude that the ideal duration and 
intensity of the schedule remains undefined, because of conflicting data 63. 
Adjuvant intravesical bacillus Calmette-Gue´rin immunotherapy 
Adjuvant intravesical bacillus Calmette-Gue’rin´ (BCG) immunotherapy is 
the treatment of choice in T1G3 TCC. Standard induction therapy is of 6 weekly 
instillations after a second resection for a diagnosed T1G3 disease. The 
therapeutic benefit of BCG for T1G3 bladder cancers has been definitively 
established 64,65,66.  
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There is evidence to support the role of maintenance BCG therapy for 
T1G3 bladder cancer. In a prospective, randomised Southwest Oncology Group 
(SWOG) trial, Lamm et al evaluated the efficacy of induction plus maintenance 
BCG to induction BCG only in 384 patients with Ta or T1 disease at high risk of 
recurrence/ progression 27. The maintenance protocol consisted of three weekly 
BCG instillations at 3 and 6 months post-TUR and semiannually thereafter, for 3 
yr. Both 5-yr recurrence free survival (RFS) (60% vs. 41%, p < 0.001) and 
progression- free survival [PFS], (76% vs. 70%, p = 0.04) were improved with 
maintenance BCG. 
MMC is a reasonable alternative with less side effects, but used only in 
situations where adjuvant BCG is contraindicated (allergy, intolerance to BCG, or 
immunosuppressed states) 27.  Patients experiencing severe side-effects from 
full-dose BCG may be considered for dose reduction, which may, however, 
compromise efficacy. Dose reductions of one-half to one-third BCG colony- 
forming units with improved side effect profiles without compromising on the 
efficacy and safety have been studied 67,68. Recent reports by Martinez-Pineiro et 
al 69 and Yoneyama et al 70 have suggested worse outcomes with low-dose 
regimens in T1G3 patients, with trends   towards reduced recurrence free 
survival. In T1G3, TCC dose reduced BCG regimens must be used with caution. 
Additional investigation of the role of reduced dose BCG is required. 
Role of immediate or early cystectomy 
The increased recurrence and progression rates associated with 
conservatively treated T1G3 TCC make cystectomy an option for some patients. 
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A number of advantages exist to this approach:  a definitive opportunity for cure, 
and appropriate treatment of understaged lesions, to name a few. Though a 
second TUR refines local cancer staging, a high percentage of patients will still 
be understaged even after second TUR. Additionally, cystectomy enables 
lymphadenectomy. As up to 18% of T1 patients have positive lymph nodes, 
cystectomy can be both diagnostic and therapeutic for nodal metastases 27. 
Lastly, cystectomy obviates the need for repeated intravesical therapies and 
simplifies follow-up. 
Cystectomy for T1G3 TCC, however, also has a number of potential 
drawbacks. The perioperative mortality and morbidity rate following cystectomy 
(at 1–6% and 30% respectively) is not trivial 27. Cystectomy may have a harmful 
impact on quality of life secondary to long-term changes in sexual, 
gastrointestinal, and genitourinary function. Finally, RC may be considered 
overtreatment for many patients as a conservative bladder-sparing approach with 
BCG is effective in around half the cases. An approach using reliable risk 
stratification is thus required to decide which patients to offer early cystectomy vs. 
where conservative treatment.  
Other Treatment Modalities  
The role of radiation therapy (RT) with or without chemotherapy for the 
treatment of T1G3 TCC is limited. Weiss et al retrospectively evaluated the 
impact of radiochemotherapy in 141 patients with T1G3 bladder cancer 71. Of the 
84 patients with T1G3  disease, 89% did not have tumour on restaging TUR six 
weeks after completion of radiochemotherapy. Long-term results, however, 
32 
 
showed that the 10-yr risk of progression for T1G3 patients was 29%. Vis a vis. 
BCG, however, the results of RT have not been as encouraging.  In the largest 
randomized trial, Harland et al compared RT to conservative therapy (observation 
or intravesical BCG/MMC) in T1G3 TCC and found no difference in progression 
free survival 72. Due to cost, inconvenience, potential for toxicity, and a lack of 
demonstrable benefit over conventional intravesical therapies, RT cannot be 
recommended for routine use as a bladder-preservation strategy. 
Is A Second TUR A Must In All T1G3 Bladder Cancers? 
Despite the existence of literature supporting a second TUR, there are a 
few investigators who still question this. Even after a satisfactory primary 
resection and presence of adequate muscle in the resected specimen, do we 
need to proceed with a second resection? Is there a sub group which can avoid a 
second TUR? The morbidity associated with invasive re-resection, the cost of the 
treatment and the delay in intravesical therapy makes one wonder if re-resection 
is required in all T1G3 lesions 
T1G3 tumors are famed for their high progression and recurrence rates. A 
vast majority of this is due to incomplete primary resection and due to absence of 
muscle in the TURT specimen. Dutta et al.  57 reported a 64% risk of 
understaging T1 lesions when muscle was absent compared with 30% when 
muscle was present in the TURBT specimens.  
Tumor architecture, (papillary or sessile, solitary or multifocality of the 
lesions) during the primary TURT are important prognostic factors for recurrence 
and progression of the disease. Solitary papillary lesions are deemed a good 
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prognostic factor over multiple papillary and sessile lesions 73. Schips et al. 24 
prospectively evaluated the findings at first and second TURBT for patients with 
high-grade T1 bladder tumors and also found residual disease in nearly 50% of 
patients.  
Both multifocality and tumor grade increased the risk of finding residual 
tumor on second TURBT.  Although 76% of patients with a solitary T1 lesion at 
first TURBT had a negative second TURBT, only 53% of those with multifocal T1 
lesions had a negative repeat TURBT. Moreover, approximately 3/4ths of  with 
papillary-appearing T1 lesions at first resection had a negative repeat TURBT 
compared with only 47% of those with solid-appearing T1 lesions. In another 
study, of 17 patients with a solitary T1G3 lesion who underwent a radical 
cystectomy after the primary TURBT, only one patient had a tumor in the 
resected specimen. The others were probably over treated 16. It has also been 
felt that re-resection may not be required in all T1G3 lesions, and the primary 
TURBT can identify the subset of aggressive T1G3 tumors 74. Invasion of lamina 
propria superficial to the muscularis mucosa (T1a) is considered a good 
prognostic factor as against the lamina propria deeper to muscularis mucosa. 
Involvement of muscularis mucosa in the lamina propria is considered T1b, and 
T1c is beyond the muscularis mucosa of lamina propria 75. Orsola et al 76 
commented on the European guidelines for NMIBC and suggested a second 
TUR in all T1 tumors.  
In our institution we analysed a few characters of these T1G3 tumors and 
attempted to answer the question: Is a second TUR necessary in all T1G3 tumors 
even after a complete primary TUR? 
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AIM OF THE STUDY 
To assess the role of second resection in T1G3 bladder tumors 
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MATERIAL AND METHODS 
This is a prospective study conducted in the Department of Urology, 
Christian Medical College, Vellore from April 2009 to December 2010. All the new 
patients who were diagnosed to have a space occupying lesion in the bladder 
and were planned for a transurethral resection of bladder tumor were assessed. 
The patient was explained in detail about the present study, the disease (Bladder 
cancer and T1G3 disease), and the management needed in the language best 
understood by the patient. Informed consent was taken for the study. Patient 
details, along with the clinical history and physical and systemic examinations 
were noted. Relevant blood and urine investigations and the radiological 
assessment were performed. Preanaesthetic evaluation was done for all the 
patients prior to the surgery. 
The procedure was conducted in the operation room under general or 
regional anesthesia. A few of the patients needed obturator block to avoid 
obturator jerk and the complications associated with it. Detailed cystoscopic 
evaluation was carried out. The bladder lesions were meticulously assessed and 
all the features including the site, size, multiplicity, relation to the ureteric orifices 
and the appearance of the rest of the bladder mucosa were recorded. 
Endoscopic, video assisted transurethral resection of the bladder tumor was 
performed or supervised by a consultant. Karl Stroz / Wolf 26 fr active cutting 
resectoscopes were used for the procedure. All the visible lesions were resected 
and the tissue sent for histopathological examination. In all the subjects, after 
complete resection of the tumor macroscopically during the primary resection, 
deeper tissue with muscle was resected and sent separately for histopathological 
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examination. The pathologists’ report of the inclusion of the muscularis propria in 
the specimen is the indication for a complete resection of the lesion.  
A dedicated uropathologist assessed all the specimens sent and the presence of 
the malignancy along with the stage, grade, and the involvement of the muscularis 
propria was specifically mentioned. A second TUR was routinely performed in all the 
pT1G3 bladder tumors within 4 – 6 weeks. Resection was performed at the previous 
resection scar sites as documented by the earlier surgery records. and also at the 
doubtful areas. Presence of any new residual or recurrent disease is specifically looked 
for and the doubtful areas resected and sent for histopathological examination. The 
resected specimen was assessed for any residual tumor, its stage, grade and upstaging 
of the disease if any.  
Statistical analysis: 
Sample size: Sample Size was calculated using the following formula 
 
  4 p q 
N =       -------- 
    d 2 
 
• Outcome = Presence/absence of re-resection 
• prevalence (p) of re-resection = 20%. 
• q = 100-p : 100-20 = 80 %. 
• precision = 10% 
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The required sample size to estimate a prevalence of 20% with a precision 
of 10% and with 95% CI was 70.  This prospective study from April 2009 to 
December 2010, aims to include this sample size in the study, but being a 
prospective and time constrained thesis, all the patients in this time period were 
included for this thesis. A total of 37 patients were diagnosed to have T1G3 
disease and of which only 27 had a second resection done. Hence, these 27 
patients were taken as the study group and the sample size. 
All the T1G3 lesions were included in this study and different variables like 
the size, multifocality, characteristics of the lesions would be analysed.  
Descriptive statistics was calculated for all study variables.  Prevalence of re-
resection was calculated along with 95% CI. Chi square test was used to assess 
association between the categorical variables and the T2 upstaging. 
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Table 1: Stage & Grade of TCC 
Association of smoking was looked at in these patients with bladder 
lesions. None of the women had any association with tobacco. Out of the 129 
patients with bladder lesions, 69 (53.48%) were regular smokers with variable 
cigarette pack years.  
Of the 129 patients who underwent TURBT, 37 patients had T1G3 TCC 
bladder. Thirty of them were men and 7 were women. The mean age of the T1G3 
patients was 57.3 years (37 – 75). Of these 37 patients with T1G3 lesions, 10 
patients did not undergo a second resection. Two patients had multiple 
Stage & Grade No. of patients (%)
TaG1 Nil 
TaG2   29   (23) 
TaG3     17   (13.5) 
T1G1   04   (3.1) 
T1G2   08   (6.3) 
T1G3     37   (29.3) 
CIS  03   (2.3) 
T2 disease    28   (22.2) 
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classified as solitary papillary, multiple papillary, sessile and multiple sessile 
lesions (Table 2).  
 
Characteristics of the lesion No. of patients (%) 
Solitary papillary 15 (55.5) 
Multiple papillary 09 (33.3) 
Solitary sessile 03 (11.1) 
Multiple sessile Nil 
Table 2: Characteristics of the primary lesion. 
Most of these tumors were located on the lateral wall (Fig 3). When there 
were multiple tumors, the site of the largest tumor was considered.  Twelve of 
these lesions were ≥3cm in size, and fifteen were < 3cm in size (Table 3) 
Size of the lesion No. of patients (%) 
                        ≥ 3cm                    12 (44.4) 
                        < 3cm                    15 (56.6) 
 Table 3: Size of the lesions. 
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There is no strong evidence to classify the tumor in the second resection 
as residual or recurrent tumor. Among the 9 patients with tumor in the second 
resection, only one patient (3.7%) had upstaging to muscle invasive disease 
(Figure 6). 
 
 
Figure 6: Tumor staging in second resection. 
Many variables like the primary characteristics of the lesion, the size of the 
lesion, muscle in the primary resection specimen and associated CIS assessed 
and correlated with the result of the second resection. Only 3 patients had a 
secondary CIS in the primary resected specimen among the study group. On the 
second resection, two were positive for tumor and one did not have tumor in the 
second resection. All the primary resections had uninvolved deep muscle in the 
specimen. 
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Out of the 9 (33.3%) patients with positive second resection, 5 (18.5%) 
had low stage disease. Two were solitary papillary and two were multiple 
papillary lesions and one was a sessile lesion. Four of them had lesions <3cm in 
size. Three patients (11.1%) had the same stage (T1G3) and 1 patient (3.7%) 
had upstaging to T2 disease. Same or higher stage disease in the second TUR is 
seen in multiple papillary (3 patients) and sessile lesion (one patient). 
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DISCUSSION 
Bladder cancer is known to occur in the elderly age group, and mostly in 
the 6th and 7th decade of life. In our study, most of the patients were in the fifth 
and sixth decade. Eventhough smoking is attributed as a risk factor which 
significantly increases the risk of bladder cancer, nearly half the patients with 
TCC in our study were nonsmokers. 
TURBT is the initial step in the management of bladder cancer. A 
technically complete primary resection is warranted for accurate pathological 
staging and grading of the tumor. After complete resection of all the visible 
tumors, deep muscle is resected separately for histopathology. If the resected 
specimen has no muscle, there is a potential for understaging T1 tumors. The 
important factor is the complete primary resection of the bladder tumor. Presence 
of the uninvolved muscularis propria in the resected specimen is the only 
identification for a complete resection 77. Retrospective studies have shown that 
residual disease can be seen in upto 68% cases 78. These high rates may also 
have been due to the fact that no muscle was present in many of the primary 
TUR specimens.  Forty nine percent of T1 lesions without muscle in the resected 
specimen were understaged when compared to only 14% with muscle in the 
resected specimen 30. Understaging was reported in 64% of T1 tumors when 
muscle was absent in the specimen versus 30% when it was present 57.  All our 
resections had muscularis propria sampled at the end of the resection and 
separately sent for HPE which were tumor free. This can explain why only 3.7% 
of our patients were upstaged at the second resection.  
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Tumor architecture, papillary or sessile, and multifocality of these lesions, 
and the size of the lesion are important prognostic factors for recurrence and 
progression of the disease. A solitary papillary lesion is considered to be a good 
prognostic factor as against multiple papillary and sessile lesions 73. In our series, 
among the 15 patients with solitary papillary lesions, two had tumor positive in the 
second resection and both of them were >3cm lesions. All the 11 solitary papillary 
lesions which were <3cm were tumor free in the second resection and 2 of the 
>3cm lesions were also free of tumor in the second resection. Perhaps this is the 
subgroup, solitary papillary with <3cm in size lesions, that are least likely to 
benefit from a second resection. Multiple papillary lesions and the sessile lesions 
had significant positivity in the second resection. More than fifty percent of the 
multiple papillary lesions and 66.6% of the sessile lesions had tumor positivity in 
the second resection. The relative risk is 4.17 times more in the multiple papillary 
group when compared to solitary lesions (RR 4.17, CI-95%, 1.01-17.18). The 
relative risk is 5 times more in the sessile group when compared with the solitary 
papillary lesions (RR 5.0, CI-95%, 1.1-22.8). The chances of tumor positivity in 
the second resection in sessile and multiple papillary groups are high and are 
statistically significant when compared to solitary papillary lesions. The patient 
who had upstaging of the disease had primary multiple papillary lesions which 
was >3cm in size.  
The size of the primary lesion is also a useful prognosticating factor in 
these lesions. Many studies have proved a lesion <3cm will have decreased 
chances of recurrence and progression and this in included in the EAU guidelines 
of non muscle invasive bladder tumor. In our study, out of 15 patients with a 
<3cm primary lesion, 14 (93.3%) of them did not have a tumor in second 
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resection. The chances of tumor positivity in the second resection are high with a 
lesion of more than 3 cm in size. The relative risk is 10 times more in the tumors 
with size more than 3cm when compared with the lesions of size <3cm. (RR 10, 
CI-95%, 1.44-69.3). The one which had a tumor in the second resection is a 
multiple papillary lesion which itself carries a poor prognosis even if size is not 
considered. 
Considering these two good prognostic factors, i.e size <3cm, and the 
solitary papillary primary lesion, a select group of patients did not benefit much 
from the second resection. In this study, all the patients with primary solitary 
papillary lesion of <3cm size were free of tumor in the second resection. Another 
factor is the invasion of lamina propria superficial to the muscularis mucosa (T1a) 
which is considered a good prognostic factor as against the lamina propria 
deeper to muscularis mucosa 75. Questions have been raised whether a second 
resection is really necessary in a well performed initial resection of high grade T1 
solitary papillary lesions of <3cm in size with only superficial invasion of lamina 
propria (T1a) with negative deep muscle biopsy  especially when  intravesical 
BCG is planned  76,77.   
A comparison of similar studies is shown in table 5.  Emphasis was not 
given to complete primary resection with curative intent in many of them. One 
series had muscle in only 63% of the primary TURBT specimens 30. In another, 
though the presence of muscularis propria was not mentioned in the primary 
TURBT and 72% of the solitary lesions were tumor free at re-resection 24. None 
had muscle in the resected specimen in another series, where 42 T1G3 patients 
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underwent primary TURBT 23. The primary characteristic of the lesion which is an 
important prognostic factor was also not considered in many of these studies.  
Table 5: Comparisons of the similar studies 
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CONCLUSION 
There is a need to improve the risk stratification to optimize the treatment 
of high grade T1 ladder cancer. With the available scientific data, a second 
resection is recommended in all patients with high grade T1 urothelial bladder 
carcinoma and it does identify residual disease and invasive disease. Patients 
with T1G3 tumors do not represent a homogenous group. Isolated solitary 
papillary lesions may be the only group where the need for the second TUR can 
be avoided. The dilemma is whether a second TUR is really necessary in a well 
performed initial resection of high grade T1 solitary small papillary lesion, with 
only superficial invasion of lamina propria (T1a). In our study, among the patients 
with solitary papillary lesion and size <3cm, none had tumor in the second TUR 
and therefore did not require a second TUR. A well designed multicentric 
prospective study with a large cohort assessing various risk factors of high grade 
T1 lesions is necessary to determine the subgroups, if any, where a second TUR 
can be avoided.  
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    INFORMED CONSENT    
Study Title:   
To assess the role of second resection of T1G3 bladder tumors. 
A. CONSENT FOR PROCEDURE 
1. I _______________________________________________ authorize the 
performance of Transurethral resection of bladder tumor (TURBT) and 
second TURBT if needed. 
 
2. I understand my diagnosis / condition to be: BLADDER TUMOR.  
 
3. I have been told about the surgery (which includes information about the 
complications), the histopathological examination of the resected tissue, 
and the management plan to be decided after the final biopsy report 
 
4. I know that the management of the disease varies with the extent of the 
disease spread (Biopsy report).  
 
5. I have been told about and understand the risks and benefits of the 
procedure. I understand that there are risks like pain, urinary tract 
infection, stricture urethra, residual and recurrence of disease, perforation 
of the urinary bladder, and the further management plan according to the 
extent of the disease spread, and in very very rare instance death.  
 
6. I understand that photographs and/or video or electronic recordings may 
occur or data collected during my procedure may be used for internal 
performance improvement or educational / publication purposes. 
 
 
 B. CONSENT FOR ANESTHESIA OR SEDATION  
I consent to the administration of anesthesia medication by or under the direction 
of the doctor. I acknowledge that I have been informed about nature of the 
planned anesthesia and that I understand the risks of anesthesia to include: head 
ache, back ache, temporary loss of sensory and motor function of the lower 
extremities, allergic reactions to medications, changes in breathing. changes a 
blood pressure and heart function, nausea and vomiting, aspiration of stomach 
contents and/or excitement. I understand that recall of the procedure is possible.  
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C. PATIENT OR LEGAL REPRESENTATIVE SIGNATURE 
  
By signing below I state that l am 18 years of age or older, or otherwise 
authorized to consent. I have read or have had explained to me the contents 
of this form. I have had a chance to ask questions and all of my questions 
have been answered.  
 
__________________________________     _________________                  
 
Signature of Patient or Legal Representative                 Name                                     
Date  
 
_____________________________________ 
Relationship in case of Guardian / Legal Representative 
 
D. PHYSICIAN STATEMENT  
 
I have explained the procedure, including the possible risks, complications, 
and anticipated risks to the patient and/or his/her representative. The patient 
and/or their representative has communicated to me that they understand the 
contents of this form.  
 
______________________________________________   
Name and Signature of the doctor.                            Date.  
 
______________________________________________    
Name and Signature of Witness      Date 
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TCC URINARY BLADDER PROFORMA    
 
Name:   H No:    URO1 / URO2 
Age:            Yrs  Sex:  M / F  Phone Numbers 
Chief Complaints:       X      months 
O / E: Bladder bimanually palpable -  Y / N. 
Creatinine:   mg%.   Cytology: 
Radiology:  USG: 
 
  IVU: 
 
  CECT: 
 
Radiology Staging: 
 
Past History: 
 
Previous biopsy: Procedure Details 
 
   Date 
   
   Bx Report 
 
   Slide review 
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Procedure:  TURBT / Cold cup biopsy / Re TURT (for recurrence)    
  Date:   Surgeon:  Assesment: 
  No. of lesions: 1 / 2 / 3 / 4 / 5 / 6 / Multiple 
  Site / Size :    Bladder neck        /          Dome   
      
Posterior wall        /         Anterior wall 
         
               Left lat wall  /  Right lat wall  
   
  Distance from orifice:   
 
  Assosiated lesions: 
   
  Appearance: Invasive / Non invasive  Bimanually 
Palpable : Y / N  
 
  Mitomycin 40mg: Y / N 
 
  Complications: 
 
Biopsy:  CIS  /  Ta  /  T1  /  T2  /  T3  /  T4 
 
    PUNLMP  /  Low Grade  /  High Grade 
     
                G1  /  G2  /  G3 
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Muscle in specimen: 
 
Options:   Survelliance   BCG   Re stage TURBT 
 
  Radical Cystectomy with Ileal Conduit 
 
  Radical Cystectomy with Orthotopic Bladder 
   
Radiotherapy /  Chemotherapy 
 
Re TURBT for STAGING 
 
Procedure:  Re TURT (for staging) 
  Date:     Surgeon: 
  Previous scars:   Recurrence: Y / N 
  No. of lesions: 1 / 2 / 3 / 4 / 5 / 6 / Multiple 
  Site / Size:    Bladder neck        /          Dome   
      
Posterior wall        /         Anterior wall 
          
               Left lat wall  /  Right lat wall  
 
  Re resection from:   
  Distance from orifice: 
  Associated lesions:   
  Appearance: Invasive / Non invasive  
 
Name: 
Hospital No.
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Bimanually:    Palpable / Not palpable 
  Mitomycin 40mg: Y / N 
  Complications: 
 
 
Biopsy:   No tumor  Same stage/grade  Up stage Down stage 
 
Previous: CIS  /  Ta  /  T1  /  T2  /  T3  /  T4       PUNLMP  /  Lw Grde  /  
Hgh Grde 
 
Now : : CIS  /  Ta  /  T1  /  T2  /  T3  /  T4       PUNLMP  /  Lw Grde  /  
Hgh Grde 
 
    
 
 
 
 
 
sno. Name: H No: Stage CIS Unit Age:    Sex Complaints GROSS TOTAL PAINLESS CLOTS sno.
Dur_comp
(months) Comorb sno.
1 Amar Ghosh 449729d 1G3 no 1 54 Male Haematuria yes yes yes yes 1 1 nil 1
2 Raman 492917d 1G3 no 1 65 Male Haematuria yes yes yes no 2 4 HT 2
3 Sisir 527627d 1G3 no 1 55 Male Haematuria yes yes yes no 3 2 nil 3
4 Parhta sen 6387934d 1G3 no 1 41 Male Haematuria yes yes yes yes 4 24 nil 4
5 Dasarath 418178d 1G3 no 2 71 Male Haematuria yes yes yes no 5 3 nil 5
6 Ahindra 471741d 1G3 no 2 63 Male Haematuria yes yes yes yes 6 4 nil 6
7 Polu yesoda 500284d 1G3 CIS 2 55 Female Haematuria yes yes yes yes 7 8 nil 7
8 Safidul 590528d 1G3 no 2 45 Male Haematuria yes yes yes no 8 60 DM 8
9 Meena 809022d 1G3 no 2 60 Female Haematuria yes yes yes no 9 6 DM 9
10 Manikkam 447798d 1G3 no 1 39 Male Haematuria yes yes yes yes 10 12 nil 10
11 Godudhar 430124d 1G3 no 1 56 Male Haematuria yes yes yes yes 11 6 nil 11
12 Lakshmi 494365c 1G3 no 1 56 Female Haematuria yes yes yes yes 12 1 HT 12
13 Chandrakala 870276c 1G3 no 1 63 Female Haematuria yes yes yes yes 13 1 nil 13
14 Bishnupada 649841d 1G3 no 1 70 Male Haematuria yes yes yes yes 14 1 nil 14
15 Ashok 271382d 1G3 no 1 49 Male Haematuria yes yes yes no 15 1 HT 15
16 Subramanyam 690289d 1G3 no 1 48 Male Haematuria yes yes yes yes 16 3 nil 16
17 Saroj Kumar 750916d 1G3 no 1 48 Male Haematuria yes yes yes no 17 2 nil 17
18 Basudev 755613d 1G3 no 1 52 Male Haematuria yes yes yes yes 18 240 nil 18
19 Jasintha 463166d 1G3 no 2 50 Female Haematuria yes yes yes no 19 12 nil 19
20 Ismail 653399d 1G3 no 2 64 Male Haematuria yes yes yes yes 20 1 DM, HT 20
21 Khudi ram 665695d 1G3 no 2 61 Male Haematuria yes yes yes no 21 3 nil 21
22 Alimuddin 740447c 1G3 no 2 75 Male Haematuria yes yes yes no 22 2 DM, HT 22
23 Rabindranath 685474d 1G3 no 2 67 Male Haematuria yes yes yes yes 23 12 HT, DM 23
24 Dhanpal 681866d 1G3 no 2 72 Male Haematuria yes yes yes yes 24 2 nil 24
25 Anderson 814437d 1G3 CIS 1 37 Male intermitency no no no no 25 1 nil 25
26 Balasundaram 938834b 1G3 no 1 49 Male Haematuria yes yes yes yes 26 4 HT, DM 26
27 Sateesh 816457d 1G3 no 2 52 Male Haematuria yes yes yes no 27 1 nil 27
O/E:Blder 
bimanly palpable - Creatinine: Cytology: USG: IVU CT Scan
Radiology 
Staging: Addictions No / day sno.
Not palpable 1.1 NS rt lat wall SOL filling defect bladder NA Non invasive Smoking 5 to 6 1
Not palpable 1 NS outside - SOL bldr NA NA Non invasive Smoking 5 to 6 2
Not palpable 0.9 NS sol bladder NA NA Non invasive Smoking 5 t0 8 3
Not palpable 0.9 NS sol bladder NA NA Non invasive Smoking 8 to 10 4
palpable 1.6 NS sol bladder NA thick rt vuj invasive No NA 5
Not palpable 1 NS outside - SOL bldr NA NA Non invasive Smoking 8 to 10 6
Not palpable 1.1 NS NA NA thick lateral wall Non invasive No NA 7
Not palpable 1 NS outside - SOL bldr NA NA Non invasive No NA 8
Not palpable 1 normal sol bladder NA NA Non invasive No NA 9
Not palpable 0.9 NS own- sol lt lat wl ,normal NA Non invasive No NA 10
Not palpable 1.2 NS post wl SOL NA NA Non invasive Smoking five to six 11
Not palpable 0.9 NS rt lat wall SOL NA NA Non invasive No NA 12
Not palpable 0.9 NS outside - SOL bldr NA NA Non invasive No NA 13
Not palpable 1.4 NS NA filling defect bladder NA Non invasive Smoking 25 to 30 14
Not palpable 1.1 NS outside - SOL bldr NA NA Non invasive No NA 15
Not palpable 1.1 NS own- sol lt lat wl filling defect bladder NA Non invasive Smoking 7 16
Not palpable 1 NS sol bladder NA NA Non invasive No NA 17
Not palpable 0.9 NS own- sol lt lat wl NA NA Non invasive No NA 18
Not palpable 0.9 NS sol bladder NA NA Non invasive No NA 19
Not palpable 1.2 NS sol bladder NA NA Non invasive Smoking 4 to 6 20
Not palpable 1.2 NS sol bladder NA NA Non invasive Smoking 6 to 8 21
Not palpable 1.6 NS sol bladder filling defect bladder NA Non invasive Smoking 3 to 5 22
Not palpable 2 NS sol bladder NA thick wall post Non invasive Smoking 6 to 8 23
Not palpable 1 normal outside - SOL bldr NA sol bladder outside Non invasive No NA 24
Not palpable 1 normal sol bladder NA sol bladder Non invasive No NA 25
Not palpable 1.2 normal sol bladder filling defect bladder NA Non invasive Smoking 8 to 10 26
Not palpable 1 normal sol bladder NA NA Non invasive No NA 27
No of yrs Occupation Procedure: Date: site character Bladder neck      Dome  Post Wall Ant wall Left lat wall sno.
15 service TURBT 5/1/2009 lateral wall multiple papillary normal 2x2 1x1 normal 3x3 1
20 service TURBT 7/14/2009 lateral wall sessile normal normal normal normal normal 2
15 service TURBT 9/1/2009 post wall multiple papillary normal normal 4x4 normal field change 3
15 business TURBT 3/24/2010 lateral wall multiple papillary normal normal 1x1 normal 5x5 4
NA business TURBT 4/12/2009 lateral wall papillary normal normal normal normal normal 5
35 coolie TURBT 6/4/2009 lateral wall multiple papillary normal normal normal 2x1 normal 6
NA house wife TURBT 9/30/2009 lateral wall multiple papillary normal normal 1x1,1x1 normal 2x2,2x2,1x1 7
NA service TURBT 12/7/2009 lateral wall papillary normal normal normal normal 5x4 8
NA nil TURBT 11/25/2010 ant wall sessile normal normal normal 3x2 normal 9
NA coolie TURBT 6/5/2009 lateral wall papillary normal normal normal normal 2x2 10
20 service TURBT 4/24/2009 lateral wall papillary normal normal normal normal normal 11
NA house wife TURBT 5/6/2009 lateral wall multiple papillary normal normal normal normal normal 12
NA house wife TURBT 6/19/2009 lateral wall multiple papillary 1x1, .5x.5 normal normal normal normal 13
10 business TURBT 4/13/2010 lateral wall papillary normal normal normal normal normal 14
NA business TURBT 5/14/2010 lateral wall papillary normal normal normal normal normal 15
20 service TURBT 5/18/2010 lateral wall papillary normal normal normal normal 5x5 16
NA service TURBT 8/10/2010 lateral wall papillary normal normal normal normal 2x2 17
NA coolie TURBT 8/20/2010 lateral wall papillary normal normal normal normal 2x2 18
NA service TURBT 25/5/2009 post wall papillary normal normal 1x2 normal normal 19
30 retierded TURBT 3/22/2010 lateral wall multiple papillary 1x1 2x1 patch normal normal normal 20
20 retierded TURBT 3/31/2010 post wall papillary normal normal 2x2 normal normal 21
25 retierded TURBT 4/12/2010 lateral wall papillary normal normal normal normal normal 22
30 service TURBT 5/20/2010 post wall papillary normal normal 2x2.5 normal normal 23
NA business TURBT 5/3/2010 post wall sessile normal normal 3x3 normal normal 24
NA business TURBT 10/29/2010 lateral wall multiple papillary normal normal normal normal normal 25
15 service TURBT 10/29/2010 lateral wall papillary normal normal normal normal normal 26
NA business TURBT 11/11/2010 post wall papillary normal normal 2x2 normal normal 27
Rt lat wall
Prostatic 
urethra
Distance from 
orifice: Assosiated lesions: Appearance: Biman palp Resection MMC 40 Cxs sno.
5x4, three small normal not involved three small paipllary adjacent to main lesion non invasive not palpable complete yes nil 1
3x3 normal right orifice involved none non invasive not palpable complete no nil 2
normal normal not involved field change over post & lat non invasive not palpable complete yes nil 3
normal normal not involved none non invasive not palpable complete yes nil 4
4x3.5 normal right orifice involved none invasive palpable complete no nil 5
6x5 normal not involved multiple paillary non invasive not palpable complete yes nil 6
normal ,NA not involved none non invasive not palpable complete yes nil 7
normal normal left orifice involved none non invasive not palpable complete yes nil 8
normal ,NA not involved none non invasive not palpable complete yes nil 9
normal normal left orifice involved none non invasive not palpable complete yes nil 10
2x2 normal not involved none non invasive not palpable complete yes nil 11
4x4, three small ,NA not involved three small paipllary adjacent to main lesion non invasive not palpable complete yes nil 12
2x2 ,NA not involved total 2 non invasive not palpable complete yes nil 13
2x2 normal not involved none non invasive not palpable complete yes nil 14
2.5x2 normal not involved none non invasive not palpable complete yes nil 15
normal normal left orifice involved none invasive not palpable complete no nil 16
normal normal not involved none non invasive not palpable complete yes nil 17
normal normal not involved none non invasive not palpable complete yes nil 18
normal ,NA not involved none non invasive not palpable complete yes nil 19
2x2 normal not involved 2x2 erythematous patch non invasive not palpable complete yes nil 20
normal normal right orifice involved none non invasive not palpable complete yes nil 21
2x2 normal not involved none non invasive not palpable complete yes nil 22
normal normal left orifice involved none non invasive not palpable complete yes nil 23
normal normal not involved none non invasive not palpable complete yes nil 24
1x1, 1x1, 1x1 normal right orifice involved none non invasive not palpable complete yes nil 25
5x5 normal not involved none non invasive not palpable complete yes nil 26
normal normal not involved none non invasive not palpable complete yes nil 27
Bx 
Stage Grade Ass CIS
Muscle
 in Bx plan
RE 
RESECTION       DATE
DIFF IN 
WEEKS SURGEON PREV SCAR sno.
1 3 no yes second rx done 6/16/2009 6 multiple scars 1
1 3 no yes second rx done 9/9/2009 7 scar + tr frm rt orifice 2
1 3 CIS yes second rx done 12/10/2009 6 scar odema 3
1 3 no yes second rx done 6/8/2010 12 scar 4
1 3 no yes second rx done 4/23/2009 6 scar + 1x1 papillary on rt UO 5
1 3 no yes second rx done 8/24/2009 11 scar & tumor 6
1 3 CIS yes second rx done 5/11/2009 5 scar & tr 7
1 3 no yes second rx done 1/18/2010 6 scar & tr 8
1 3 no yes second rx done 1/24/2011 8 scar 9
1 3 no yes second rx done 6/16/2009 6 odematous scar 10
1 3 no yes second rx done 5/12/2009 3 scar 11
1 3 no yes second rx done 7/10/2009 5 scar 12
1 3 no yes second rx done 8/11/2009 7 scar 13
1 3 no yes second rx done 4/6/2010 7 scar 14
1 3 no yes second rx done 6/16/2010 4 scar 15
1 3 no yes second rx done 2/7/2010 6 scar 16
1 3 no yes second rx done 10/9/2010 4 scar 17
1 3 no yes second rx done 9/22/2010 4 scar 18
1 3 no yes second rx done 7/22/2009 7 scar 19
1 3 CIS yes second rx done 6/17/2010 11 11 erythematous scar 20
1 3 no yes second rx done 5/27/2010 8 scar 21
1 3 no yes second rx done 5/23/2010 5 scar 22
1 3 no yes second rx done 7/13/2010 7 scar 23
1 3 no yes second rx done 6/24/2010 7 scar 24
1 3 CIS yes second rx done 1/14/2011 10 scar 25
1 3 no yes second rx done 1/25/2011 11 scar 26
1 3 no yes second rx done 12/22/2010 6 scar 27
RECURRENCE
      No. OF 
LESIONS           Site
BLDER 
NK   DOME ANT WAL POST WAL LT LAT sno.
yes multiple PW, rt & lt LW normal scar 1x1 1x1, 1x1 1x1 1
yes 1 rt orifice normal normal normal normal normal 2
odema odema post wall odema normal normal normal odematous scar normal 3
nil nil lat wall normal normal normal normal scar 4
1x1 rt UO 1 rt orifice normal normal normal normal normal 5
1x1 & .5x.5 on scar, 3 on scar, rt lateral wall normal normal normal normal 5x5mm 6
2x2mmon scar, 2x2mm ant wall 2 on scar and ant wall normal normal 2x2mm normal 3x3mm 7
2x2cm scar & 1x1 tr 1 on scar area normal normal normal normal scar & 1x1 tr 8
scar ant wall scar normal normal scar normal normal 9
nil nil scar normal normal normal normal scar 10
nil nil scar normal normal normal normal normal 11
nil nil scar normal normal normal normal normal 12
nil nil scar normal normal normal normal normal 13
nil nil scar normal normal normal normal normal 14
nil nil scar normal normal normal normal normal 15
nil nil scar normal normal normal normal scar 16
nil nil scar normal normal normal normal scar 17
nil nil scar normal normal normal normal scar 18
nil nil scar normal normal normal scar normal 19
2x2cm scar & 1x1 tr 1 on scar contracture normal normal normal normal 20
2x2 scar scar normal normal normal scar normal 21
4x3 scar , scar normal normal normal normal normal 22
2x2 scar , scar normal normal normal scar normal 23
2x2 scar , scar normal normal normal scar normal 24
scar 1 rt lateral wall normal normal normal normal normal 25
scar , rt lateral wall normal normal normal normal normal 26
scar post wall scar normal normal normal scar normal 27
RT LAT DIST Fm ORIFICE
APPEARANCE 
of scar
ASS. 
LESIONS BIMANUALLY RESECTION Cx MMC BIOPSY sno.
1x1 not involved recurence on scars multiple not palpable complete nil no T1G3 1
3x3 r orifice rt involved recurence on scars nil not palpable complete nil no TaG3 2
normal not involved odematous nil not palpable complete nil no T1G3 3
normal not involved normal not palpable complete nil no T2G3 4
scar + rec involved recurence on scars nil not palpable complete nil no TaG3 5
1x1 & .5x.5 on scar, not involved recurrence on scar 1 not palpable complete nil no TaG3 6
normal not involved recurrence two not palpable complete nil no TaG3 7
normal not involved recurrence nil not palpable complete nil no TaG3 8
normal not involved normal nil not palpable complete nil no T1G3 9
normal scar normal nil not palpable complete nil No no malignancy 10
scar not involved normal nil not palpable complete nil No no malignancy 11
scar not involved normal nil not palpable complete nil no no malignancy 12
scar not involved normal nil not palpable complete nil no no malignancy 13
scar not involved normal nil not palpable complete nil no no malignancy 14
scar not involved normal nil not palpable complete nil No no malignancy 15
normal left orifice not seen - scar odematous nil not palpable complete nil No no malignancy 16
normal not involved normal nil not palpable complete nil No no malignancy 17
normal not involved normal nil not palpable complete nil No no malignancy 18
normal not involved normal nil not palpable complete nil no no malignancy 19
scar not involved normal nil not palpable complete nil no no malignancy 20
normal involved normal nil not palpable complete nil no no malignancy 21
scar not involved normal nil not palpable complete nil no no malignancy 22
normal not involved normal nil not palpable complete nil no no malignancy 23
normal not involved normal nil not palpable complete nil no no malignancy 24
scar not involved normal nil not palpable complete nil no no malignancy 25
scar not involved normal nil not palpable complete nil no no malignancy 26
normal not involved normal nil not palpable complete nil no no malignancy 27
     Bx STAGE Bx GRADE
  UP/DOWN 
STAGE
1 3 same
a 3 down
1 3 same
2 3 upstage
a 3 down
a 3 down
a 3 down
a 3 down
1 3 same
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
na na na
